Benzodiazepine derivatives
    2.
    发明授权
    Benzodiazepine derivatives 失效
    苯并二氮杂衍生物

    公开(公告)号:US5521175A

    公开(公告)日:1996-05-28

    申请号:US374749

    申请日:1995-01-26

    摘要: Compounds of Formula (I), and salts and prodrugs thereof, wherein R.sup.1 represents C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 optionally substituted phenyl or R.sup.2 represents a group (A) where W is CH.sub.2 or NR.sup.10, and W.sup.1 is CH.sub.2, or W and W.sup.1 each represent 0; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.13 R.sup.14 ; R.sup.4 is H, C.sub.1-4 alkyl, optionally substituted phenyl or optionally substituted benzyl; R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are H or C.sub.1-4 alkyl; or any two of R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 together form a chain (CH.sub.2).sub.t, and any other two of R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 optionally form a chain (CH.sub.2).sub.s where s and t are independently 1, 2 or 3; m is 2, 3, 4, 5, 6, 7, 8 or 9; n is 0, 1, 2, 3 or 4; and x is 0, 1, 2 or 3; are CCK and/or gastrin antagonists useful in therapy. ##STR1##

    摘要翻译: PCT No.PCT / GB93 / 01600 Sec。 371日期1995年1月26日 102(e)日期1995年1月26日PCT提交1993年7月28日PCT公布。 第WO94 / 03447号公报 日期:1994年2月17日。式(I)化合物及其盐和前药,其中R 1表示C 1-6烷基或C 3-7环烷基; R2任选取代的苯基或R 2表示其中W是CH 2或NR 10,且W 1是CH 2的基团(A),或者W和W 1各自表示0; R3是C1-6烷基,卤素或NR13R14; R 4是H,C 1-4烷基,任选取代的苯基或任选取代的苄基; R5,R6,R7和R8是H或C1-4烷基; 或R 4,R 5,R 6,R 7和R 8中的任何一个一起形成链(CH 2)t,并且R 4,R 5,R 6,R 7和R 8中的任何其它两个可任选地形成链(CH 2)s,其中s和t独立地 1,2或3; m为2,3,4,5,6,7,8或9; n为0,1,2,3或4; x为0,1,2或3; 是用于治疗的CCK和/或胃泌素拮抗剂。 (图)(一)

    Benzodiazepine derivatives, compositions containing them and their use
in therapy
    3.
    发明授权
    Benzodiazepine derivatives, compositions containing them and their use in therapy 失效
    苯并二氮杂衍生物,含有它们的组合物及其在治疗中的用途

    公开(公告)号:US5451582A

    公开(公告)日:1995-09-19

    申请号:US16646

    申请日:1993-02-12

    CPC分类号: C07D403/12 C07D243/14

    摘要: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein: R.sup.1 is H, certain optionally substituted C.sub.1.6 alkyl, or C.sub.3-7 cycloalkyl;R.sup.2 is (CH.sub.2).sub.q -tetrazolyl optionally substituted in the tetrazole ring by C.sub.1-4 alkyl, (CH.sub.2).sub.q -imidazolyl (where q is 0, 1, 2 or 3), CONHSO.sub.2 R.sup.9, SO.sub.2 NHCOR.sup.9 (where R.sup.9 is C.sub.1-6 alkyl, optionally substituted aryl or trifluoromethyl). SO.sub.2 NHR.sup.10 (where R.sup.10 is a nitrogen containing heterocycle), cyclopropyl or (CH.sub.2), CO.sub.2 H, where n is 1 or 2;R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ;R.sup.4 is C.sub.1-7 straight or branched chain alkyl; andx is 0, 1, 2 or 3;are CCK and/or gastrin receptor antagonists. They and compositions thereof are useful in therapy.

    摘要翻译: 式(I)化合物及其盐和前药其中:R 1为H,某些任选取代的C 1-6烷基或C 3-7环烷基; (CH 2)q-咪唑基(其中q为0,1,2或3),CONHSO 2 R 9,SO 2 NHCOR 9(其中R 9为C 1-6烷基,任选地为(CH 2)q-四唑基) 取代的芳基或三氟甲基)。 SO2NHR10(其中R10是含氮杂环),环丙基或(CH2),CO2H,其中n为1或2; R3是C1-6烷基,卤素或NR6R7; R4是C1-7直链或支链烷基; x为0,1,2或3; 是CCK和/或胃泌素受体拮抗剂。 它们及其组合物可用于治疗。

    Benzodiazepine derivatives, compositions containing them and their use
in therapy
    5.
    发明授权
    Benzodiazepine derivatives, compositions containing them and their use in therapy 失效
    苯并二氮杂衍生物,含有它们的组合物及其在治疗中的用途

    公开(公告)号:US5597915A

    公开(公告)日:1997-01-28

    申请号:US295918

    申请日:1994-09-15

    CPC分类号: C07D413/10

    摘要: Compounds of Formula (I), and salts and prodrugs thereof wherein: R.sup.1 is H, certain optionally substituted C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 represents a group (a) wherein X is O, S or NR.sup.8 where R.sup.8 is H or C.sub.1-4 alkyl; one of Z and Y is C.dbd.O and the other is O, S or NR.sup.9, where R.sup.9 is H or C.sub.1-4 alkyl; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 is C.sub.3-10 cycloalkyl; n is 0, 1, 2 or 3, and are CCK and/or gastrin antagonists, which compounds and compositions thereof are useful in therapy.

    摘要翻译: PCT No.PCT / GB93 / 00535 Sec。 371日期1994年9月15日 102(e)1994年9月15日PCT 1993年3月15日PCT公布。 公开号WO93 / 19063 (I)化合物及其盐和前体药物其中:R 1是H,某些任选取代的C 1-6烷基或C 3-7环烷基; R2表示其中X为O,S或NR8的基团(a),其中R8为H或C1-4烷基; Z和Y之一是C = O,另一个是O,S或NR 9,其中R 9是H或C 1-4烷基; R3是C1-6烷基,卤素或NR6R7; R4为C3-10环烷基; n为0,1,2或3,为CCK和/或胃泌素拮抗剂,其化合物及其组合物可用于治疗。

    Imidazole, Triazole and tetrazole derivatives
    6.
    发明授权
    Imidazole, Triazole and tetrazole derivatives 失效
    咪唑,三唑和四唑衍生物

    公开(公告)号:US5567726A

    公开(公告)日:1996-10-22

    申请号:US374582

    申请日:1995-01-24

    摘要: Imidazole, triazole and tetrazole derivatives of formula (I) are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated, wherein the broken circle represents two non-adjacent double bonds in any position in the five-membered ring; two, three or four of V, W, X, Y and Z represent nitrogen and the remainder represent carbon provided that, when two of V, W, X, Y and Z represent nitrogen and the remainder represent carbon, then the said nitrogen atoms are in non-adjacent positions within the five-membered ring; E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; F represents a group of formula (a); U represents nitrogen or C--R.sup.2 ; B represents oxygen, sulphur or N--R.sup.3 ; R.sup.1 represents a group of formula (i), (ii) or (iii).

    摘要翻译: PCT No.PCT / GB93 / 01495 Sec。 371日期1995年1月24日 102(e)1995年1月24日PCT PCT 1993年7月15日PCT公布。 第WO94 / 02477号公报 (i)式(I)的咪唑,三唑和四唑衍生物是选择性激动剂(I) 的5-HT1样受体,因此可用于治疗临床状况,特别是指示这些受体的选择性激动剂的偏头痛和相关病症,其中所述断圆代表任何位置的两个不相邻的双键 在五元环中; V,W,X,Y和Z中的两个,三个或四个表示氮,余数表示碳,条件是当V,W,X,Y和Z中的两个表示氮并且其余表示碳时,则所述氮原子 在五元环内的非相邻位置; E表示含有1至4个碳原子的键或直链或支链亚烷基链; F表示式(a)的基团。 U表示氮或C-R2; B代表氧,硫或N-R3; R1表示式(i),(ii)或(iii)的基团。

    Heteroaromatic 5-hydroxytryptamine receptor agonists
    7.
    发明授权
    Heteroaromatic 5-hydroxytryptamine receptor agonists 失效
    杂芳族5-羟色胺受体激动剂

    公开(公告)号:US5510359A

    公开(公告)日:1996-04-23

    申请号:US318610

    申请日:1994-10-07

    CPC分类号: C07D413/10 C07D417/12

    摘要: A class of substituted five-membered heteroaromatic compounds possessing an imino spacer group are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.

    摘要翻译: PCT No.PCT / GB93 / 00789 Sec。 371日期:1994年10月7日 102(e)日期1994年10月7日PCT提交1993年4月14日PCT公布。 公开号WO93 / 21182 一类具有亚氨基间隔基团的取代的五元杂芳族化合物是5-HT1样受体的选择性激动剂,因此可用于治疗临床病症,特别是偏头痛和相关疾病,用于 其中指出了这些受体的选择性激动剂。

    Thienodiazepine derivatives as cholecystokinin and gastrin antagonists
    9.
    发明授权
    Thienodiazepine derivatives as cholecystokinin and gastrin antagonists 失效
    噻吩二氮卓衍生物作为胆囊收缩素和胃泌素拮抗剂

    公开(公告)号:US5602125A

    公开(公告)日:1997-02-11

    申请号:US392778

    申请日:1995-02-28

    IPC分类号: C07D495/04 A61K31/55

    CPC分类号: C07D495/04

    摘要: Thienodiazepine compounds of formula (1) wherein: R.sup.1 represents H, optionally substituted C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 represents optionally substituted phenyl; or R.sup.2 represents a group (a) where W is CH.sub.2 or NR.sup.9 and W.sup.1 is CH.sub.2 or W and W.sup.1 are each O; R.sup.3 is C.sub.3-7 cycloalkyl optionally substituted by one or more C.sub.1-4 alkyl groups, or R.sup.3 is NR.sup.11 R.sup.12, where R.sup.11 and R.sup.12 are each H; C.sub.1-12 alkyl optionally substituted by NR.sup.9 R.sup.9 or an azacyclic or azabicyclic group; C.sub.4-9 cycloalkyl optionally substituted by one or more C.sub.1-4 alkyl groups; C.sub.4-9 cycloalkylC.sub.1-4 alkyl optionally substituted in the cycloalkyl ring by one or more C.sub.1-4 alkyl groups; optionally substituted aryl; optionally substituted arylC.sub.1-6 alkyl; or azacyclic or azabicyclic groups; or R.sup.11 and R.sup.12 together form the residue of an optionally substituted azacylcic or azabicyclic ring system; and salts or prodrugs thereof are CCK and/or gastrin receptor antagonists useful in therapy.

    摘要翻译: PCT No.PCT / GB93 / 01782 Sec。 371日期1995年2月28日 102(e)1995年2月28日PCT PCT 1993年8月20日PCT公布。 出版物WO94 / 05673 (I)式(1)的噻吩并二氮化合物,其中:R 1表示H,任选取代的C 1-6烷基或C 3-7环烷基; R 2表示任选取代的苯基; 或R 2表示其中W为CH 2或NR 9且W 1为CH 2或W且W 1为O的基团(a) R3是任选被一个或多个C 1-4烷基取代的C 3-7环烷基,或者R 3是NR 11 R 12,其中R 11和R 12各自为H; 任选被NR 9 R 9或氮杂环或氮杂双环基团取代的C 1-12烷基; 任选被一个或多个C 1-4烷基取代的C 4-9环烷基; 任选在环烷基环中被一个或多个C 1-4烷基取代的C 4-9环烷基C 1-4烷基; 任选取代的芳基; 任选取代的芳基C 1-6烷基; 或氮杂环或氮杂双环基团; 或R 11和R 12一起形成任选取代的氮酰胆碱或氮杂双环体系的残基; 其盐或前药是可用于治疗的CCK和/或胃泌素受体拮抗剂。

    Pyrrolo-pyridine derivatives
    10.
    发明授权
    Pyrrolo-pyridine derivatives 失效
    吡咯并吡啶衍生物

    公开(公告)号:US5604240A

    公开(公告)日:1997-02-18

    申请号:US559320

    申请日:1995-11-16

    IPC分类号: C07D471/04 A61K31/435

    CPC分类号: C07D471/04

    摘要: A class of substituted pyrrolo[2,3-c]pyridine derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.

    摘要翻译: 一类取代的吡咯并[2,3-c]吡啶衍生物是5-HT1样受体的选择性激动剂,因此可用于治疗这些受体的选择性激动剂的临床病症,特别是偏头痛和相关疾病 被指示。